Want to see IL:NRGN full AI Analyst Report?
NRGN Stock Chart & Stats
204.80
0.03(0.96%)
At close: 4:00 PM EST
204.80
0.03(0.96%)
Day’s Range― - ―
52-Week Range190.80 - 305.90
Previous CloseN/A
Volume1.26K
Average Volume (3M)27.56K
Market Cap
₪26.95M
Enterprise Value5.76M
Total Cash (Recent Filing)₪5.30M
Total Debt (Recent Filing)₪181.00K
Price to Earnings (P/E)―
Beta0.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,327,785
10 Day Avg. Volume57,803
30 Day Avg. Volume27,561
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.94
Price to Sales (P/S)2.64
P/FCF Ratio116.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin RecoveryA 251% revenue rebound and a material gross margin improvement to ~60.6% signal a durable improvement in product-market fit and unit economics. Sustained higher gross margins support scalable software/service economics and improve the path to long-term profitability as revenue scales.
Improving Cash GenerationConversion to positive operating cash flow and a small positive free cash flow mark a structural shift from prior multi-year cash burn. If sustained, this reduces refinancing risk, enables reinvestment in R&D and sales, and provides a more stable base to scale operations over the next several quarters.
Proprietary Platform & Monetization ModelOwning a specialized Genomics Suite and offering both software subscriptions and project services creates sticky relationships and multiple revenue streams. The technical complexity and domain expertise raise barriers to entry and support recurring revenue potential from breeding and research customers.
Bears Say
Ongoing Large LossesPersistent wide negative margins indicate the business has not yet achieved operating leverage. Continued losses reduce retained earnings and limit ability to self-fund growth or absorb shocks, increasing reliance on external capital and constraining long-term strategic optionality.
Small, Volatile Free Cash FlowAlthough FCF turned slightly positive in 2025, its small size and a >100% year-over-year decline highlight fragility. Volatile, limited FCF relative to reported losses weakens the durability of self-funding for R&D or expansion and raises re-financing risk during slower quarters.
Limited Scale And Execution CapacityA very small team (23 employees) and scant public detail on large partnerships or contract concentration suggest capacity and execution constraints. Scaling enterprise genomics projects typically requires broader resources; concentration risk can impede revenue diversification and delivery at scale.
NRGN FAQ
What was NRGENE TECHNOLOGIES LTD’s price range in the past 12 months?
NRGENE TECHNOLOGIES LTD lowest stock price was 190.80 and its highest was 305.90 in the past 12 months.
What is NRGENE TECHNOLOGIES LTD’s market cap?
NRGENE TECHNOLOGIES LTD’s market cap is ₪26.95M.
When is NRGENE TECHNOLOGIES LTD’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NRGENE TECHNOLOGIES LTD’s earnings last quarter?
Currently, no data Available
Is NRGENE TECHNOLOGIES LTD overvalued?
According to Wall Street analysts NRGENE TECHNOLOGIES LTD’s price is currently Overvalued.
Does NRGENE TECHNOLOGIES LTD pay dividends?
NRGENE TECHNOLOGIES LTD does not currently pay dividends.
What is NRGENE TECHNOLOGIES LTD’s EPS estimate?
NRGENE TECHNOLOGIES LTD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NRGENE TECHNOLOGIES LTD have?
NRGENE TECHNOLOGIES LTD has 13,327,785 shares outstanding.
What happened to NRGENE TECHNOLOGIES LTD’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NRGENE TECHNOLOGIES LTD?
Currently, no hedge funds are holding shares in IL:NRGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NRGENE TECHNOLOGIES LTD
NRGene Technologies Ltd is an AI-powered genomics firm that designs sophisticated computational tools and advanced algorithms, serving clients globally across North America, Europe, the Middle East, Africa, and Asia Pacific. The company provides specialized software applications and complete, ready-to-use solutions for various sectors, including agricultural breeding, food technology, academia, research institutions, and agribiotech enterprises. Additionally, NRGene develops custom genetic panels tailored for a broad range of plants, from staple crops like wheat, canola, corn, soybeans, and maize to cannabis. Established in 2009, its headquarters are located in Ness Ziona, Israel.